In vitro metabolism and in vivo pharmacokinetics of bentysrepinine (Y101), an investigational new drug for anti-HBV-infected hepatitis: focus on interspecies comparison

References

• Ahn S, Kearbey JD, Li CM, et al. (2011). Biotransformation of a novel antimitotic agent, I-387, by mouse, rat, dog, monkey, and human liver microsomes and in vivo pharmacokinetics in mice. Drug Metab Dispos 39:636–43.
   PubMed Web of Science ®Google Scholar
• Baillie TA, Cayen MN, Fouda H, et al. (2002). Drug metabolites in safety testing. Toxicol Appl Pharmacol 182:188–96.
   PubMed Web of Science ®Google Scholar
• Baranczewski P, Stańczak A, Kautiainen A, et al. (2006). Introduction to early in vitro identification of metabolites of new chemical entities in drug discovery and development. Pharmacol Rep 58:341–52.
   PubMed Web of Science ®Google Scholar
• Börgel, F, Galla, F, Lehmkuhl, K, et al. (2019). Pharmacokinetic properties of enantiomerically pure GluN2B selective NMDA receptor antagonists with 3-benzazepine scaffold. J Pharm Biomed Anal 172:214–22.  
   Google Scholar
• Chang J, Guo JT. (2015). Treatment of chronic hepatitis B with pattern recognition receptor agonists: current status and potential for a cure. Antiviral Res 121:152–9.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhu J. (2013). Anti-HBV effect of individual traditional Chinese herbal medicine in vitro and in vivo: an analytic review. J Viral Hepat 20:445–52.
   PubMed Web of Science ®Google Scholar
• Cruciani G, Valeri A, Goracci L, et al. (2014). Flavin monooxygenase metabolism: why medicinal chemists should matter. J Med Chem 57:6183–96.
   PubMed Web of Science ®Google Scholar
• De Buck, SS, Sinha, VK, Fenu, LA, et al. (2007). The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab Dispos. 35:649–59. 
   Google Scholar
• Diao X, Carlier J, Zhu M, et al. (2017). In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201). Forensic Toxicol 35:20–32.
   PubMed Web of Science ®Google Scholar
• Ellefsen KN, Wohlfarth A, Swortwood MJ, et al. (2016). 4-Methoxy-α-PVP: in silico prediction, metabolic stability, and metabolite identification by human hepatocyte incubation and high-resolution mass spectrometry. Forensic Toxicol 34:61–75.
   PubMed Web of Science ®Google Scholar
• Fan HR, Ci XY, Li W, et al. (2016). The in vitro transport mechanism of bentysrepinine: a novel anti-hepatitis B virus drug candidate. Acta Pharm Sin 51:1233–9.
   Google Scholar
• Fan H, Hu Z, Li R, et al. (2017). Metabolite identification of bentysrepinine (Y101), a novel anti-HBV agent in rats using a five-step strategy based on a combined workflow with two different platforms of liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 1040:118–28.
   PubMed Web of Science ®Google Scholar
• Fan H, Li R, Gu Y, et al. (2012). Quantitation of bentysrepinine (Y101) in rat plasma by liquid chromatography tandem mass spectrometry: application to pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 889–890:103–9.
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. (2009). Guidance on M3(R2) nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2__Guideline.pdf
   Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ, et al. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215–36.
   PubMed Web of Science ®Google Scholar
• Huang J, Bathena SP, Alnouti Y. (2010). Metabolite profiling of praziquantel and its analogs during the analysis of in vitro metabolic stability using information-dependent acquisition on a hybrid triple quadrupole linear ion trap mass spectrometer. Drug Metab Pharmacokinet 25:487–99.
   PubMed Web of Science ®Google Scholar
• Joo J, Wu Z, Lee B, et al. (2015). In vitro metabolism of an estrogen-related receptor γ modulator, GSK5182, by human liver microsomes and recombinant cytochrome P450s. Biopharm Drug Dispos 36:163–73.
   PubMed Web of Science ®Google Scholar
• Kalgutkar AS, Dalvie DK, O'Donnell JP, et al. (2002). On the diversity of oxidative bioactivation reactions on nitrogen-containing xenobiotics. Curr Drug Metab 3:379–424.
   PubMed Web of Science ®Google Scholar
• Kola I, Landis J. (2004). Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–6.
   PubMed Web of Science ®Google Scholar
• Levrero M, Pollicino T, Petersen J, et al. (2009). Control of cccDNA function in hepatitis B virus infection. J Hepatol 51:581–92.
   PubMed Web of Science ®Google Scholar
• Liu X, Huang C, Xue L, et al. (2018). Simultaneous determination of bentysrepinine (Y101) and its metabolites M8 and M9 in human plasma by UPLC-MS/MS and its application to a pharmacokinetic study. J Pharm Biomed Anal 150:287–93.
   PubMed Web of Science ®Google Scholar
• Liu Q, Wang C, He S, et al. (2012). Effects of phenylalanine dipeptide compound Y101 on DHBV-DNA. Chin Pharmacol Bull 28:1389–93.
   Google Scholar
• Locarnini S, Hatzakis A, Heathcote J, et al. (2004). Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 9:679–93.
   PubMed Web of Science ®Google Scholar
• Lucifora J, Xia Y, Reisinger F, et al. (2014). Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343:1221–8.
   PubMed Web of Science ®Google Scholar
• McNaney CA, Drexler DM, Hnatyshyn SY, et al. (2008). An automated liquid chromatography-mass spectrometry process to determine metabolic stability half-life and intrinsic clearance of drug candidates by substrate depletion. Assay Drug Dev Technol 6:121–9.
   PubMed Web of Science ®Google Scholar
• Meng F, Xu W, Li Y, et al. (2015). In silico molecular docking study of repensine and bentysrepinine against HBV DNA polymerase. Chin Herbal Med 7:39–44.
   Web of Science ®Google Scholar
• Nishimura T, Kato Y, Amano N, et al. (2008). Species difference in intestinal absorption mechanism of etoposide and digoxin between cynomolgus monkey and rat. Pharm Res 25:2467–76.
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Manolakopoulos S, Dusheiko G, et al. (2008). Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 8:167–78.
   PubMed Web of Science ®Google Scholar
• Qiu J, Xu B, Huang Z, et al. (2011). Synthesis and biological evaluation of Matijing-Su derivatives as potent anti-HBV agents. Bioorg Med Chem 19:5352–60.
   PubMed Web of Science ®Google Scholar
• Ring, BJ, Chien, JY, Adkison, KK, et al. (2011). PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance. J Pharm Sci.100:4090–110. 
   Google Scholar
• Takeuchi T, Yoshitomi S, Higuchi T, et al. (2006). Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. Pharm Res 23:1460–72.
   PubMed Web of Science ®Google Scholar
• Uetrecht J. (2002). N-oxidation of drugs associated with idiosyncratic drug reactions. Drug Metab Rev 34:651–65.
   PubMed Web of Science ®Google Scholar
• Wang MY, Yang M, Hou PY, et al. (2018). Intestinal absorption of pallidifloside D are limited by P-glycoprotein in mice. Xenobiotica 48:739–44.
   PubMed Web of Science ®Google Scholar
• Waters NJ, Jones R, Williams G, et al. (2008). Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. J Pharm Sci 97:4586–95.
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2015). Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection.
   Google Scholar
• Xu B, Huang Z, Liu C, et al. (2009). Synthesis and anti-hepatitis B virus activities of Matijing-Su derivatives. Bioorg Med Chem 17:3118–25.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang X, Wang G, et al. (2018). Preclinical pharmacokinetics of C118P, a novel prodrug of microtubules inhibitor and its metabolite C118 in mice, rats, and dogs. Molecules 23:pii:2883.
   PubMed Web of Science ®Google Scholar